Biomotum

Biomotum is a private, pre-revenue medical device startup founded in 2019 and based in Cambridge, USA. The company is developing the SPARK, an on-demand robotic exoskeleton system for gait rehabilitation in clinical settings, targeting patients with stroke, cerebral palsy, and other neurological conditions. With a planned international launch in early 2026, Biomotum is currently engaging select clinics as pilot partners to evaluate its technology. The company is led by a team of engineers and entrepreneurs and is advised by experts in medical device development, regulatory strategy, and commercialization.

Wearable robotic exoskeleton system (SPARK) for clinical gait rehabilitation, providing on-demand assistance to improve walking speed, endurance, and coordination in patients with neurological impairments.

Biomotum operates in the competitive rehabilitation robotics market, facing competition from companies like Ekso Bionics and ReWalk (which focus more on overground walking for spinal cord injury) and from makers of stationary gait training robots like Hocoma. Its key differentiator is its specific focus on a clinic-based, on-demand exoskeleton for stroke and cerebral palsy, aiming for integration into standard neurologic rehab workflows.